The Defense Health Agency awarded The University of Texas M.D. Anderson Cancer Center $559,001 on November 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to evaluate a multimodality platform of tissue-, blood-, and advanced imaging-based predictive biomarkers to neoadjuvant immunotherapy and radiotherapy response in mucosal melanoma. Work will be performed in Houston, Texas, with a period of performance through October 31, 2028. This award is a Project Grant assistance type. The modification corrected the total award amount listed on the contract line item; all other terms and conditions remain unchanged.